Publication: Serum oncofetal fibronectin (onfFN) mrna in differentiated thyroid carcinoma (DTC): Large overlap between disease- free and metastatic patients
No. of Pages/File Size
Asian Pacific Journal of Cancer Prevention. Vol.13, No.8 (2012), 4203-4208
Chanika Sritara, Putthiporn Charoenphun, Mathurose Ponglikitmongkol, Suchawadee Musikarat, Chirawat Utamakul, Payap Chokesuwattanasakul, Ammarin Thakkinstian (2012). Serum oncofetal fibronectin (onfFN) mrna in differentiated thyroid carcinoma (DTC): Large overlap between disease- free and metastatic patients. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/13836.
Serum oncofetal fibronectin (onfFN) mrna in differentiated thyroid carcinoma (DTC): Large overlap between disease- free and metastatic patients
Aim: This study assessed if onfFN mRNA in the peripheral blood of patients with DTC can identify individuals with metastatic disease. Methods: Comparison of onfFN mRNA was made among 3 groups: disease-free, lymph node metastasis, and distant metastasis using real-time RT-PCR on 5 ml blood samples from each DTC patient. Results: Fifty-one patients were included: 30 (59%) were disease-free; 7 (13.7%) had lymph node metastasis; and 14 (27.5%) had distant metastasis. OnfFN mRNA levels in the 3 groups were significantly different (P=0.001) but with a large overlap and the expression being highest in the disease-free group. Subgroup analysis of the metastatic groups did not show any effect of age, cell type, and serum TSH, Tg, and antiTg on onfFN mRNA. The within-run and between-run root mean square coefficients of variations were < 2%. Conclusion: OnfFN mRNA in patients with DTC cannot identify those with metastatic disease.